|Dr. Phillip Louis Gomez III||CEO & Director||1.66M||N/A||1967|
|Mr. Daniel J. Luckshire||Exec. VP, CFO & Sec.||1.04M||N/A||1971|
|Dr. Dennis E. Hruby||VP & Chief Scientific Officer||1.16M||327.38k||1952|
|Ms. Robin E. Abrams||Gen. Counsel & Chief Admin. Officer||1.01M||N/A||1964|
|Dr. Eric A. Rose||Consultant||732.17k||437.1k||1951|
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 4; Compensation: 7.